Works matching IS 14397595 AND DT 2024 AND VI 34 AND IP 2


Results: 27
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice.

    Published in:
    Modern Rheumatology, 2024, v. 34, n. 2, p. 307, doi. 10.1093/mr/road027
    By:
    • Tsukasa Matsubara;
    • Kou Katayama;
    • Akira Sagawa;
    • Masaaki Yoshida;
    • Takeshi Mitsuka;
    • Keisuke Hashimoto;
    • Tomomaro Izumihara;
    • Masakazu Kondo;
    • Tomomasa Izumiyama;
    • Nobumasa Miyake;
    • Ichiro Yoshii;
    • Motohiro Oribe;
    • Shigeki Momohara;
    • Keiko Funahashi
    Publication type:
    Article
    23

    Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)

    Published in:
    Modern Rheumatology, 2024, v. 34, n. 2, p. 297, doi. 10.1093/mr/road045
    By:
    • Kenta Misaki;
    • Naoto Tamura;
    • Takanori Azuma;
    • Koichiro Shinoda;
    • Masao Tanaka;
    • Hiroshi Fujiwara;
    • Hideki Tsuboi;
    • Tsuyoshi Kasama;
    • Ryusuke Yoshimi;
    • Tadamasa Hanyu;
    • Yoshiaki Kusaka;
    • Makoto Hirao;
    • Makoto Onishi;
    • Ayumi Uchino;
    • Tomomasa Izumiyama;
    • Kwang-Seok Yang;
    • Noriyoshi Ogawa;
    • Kiyoshi Matsui;
    • Kazuhiro Kurasawa;
    • Satoshi Kawaai
    Publication type:
    Article
    24

    Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.

    Published in:
    Modern Rheumatology, 2024, v. 34, n. 2, p. 287, doi. 10.1093/mr/road031
    By:
    • Masayoshi Harigai;
    • Takao Fujii;
    • Ryoko Sakai;
    • Ataru Igarashi;
    • Ayako Shoji;
    • Hiroko Yamaguchi;
    • Katsuhiko Iwasaki;
    • Misako Makishima;
    • Amika Yoshida;
    • Norihiro Okada;
    • Katsuhisa Yamashita;
    • Yutaka Kawahito
    Publication type:
    Article
    25
    26

    The impact of the COVID-19 pandemic on SLE.

    Published in:
    Modern Rheumatology, 2024, v. 34, n. 2, p. 247, doi. 10.1093/mr/road030
    By:
    • Xingwang Zhao;
    • Haohao Wu;
    • Shifei Li;
    • Cuie Gao;
    • Juan Wang;
    • Lan Ge;
    • Zhiqiang Song;
    • Bing Ni;
    • Yi You
    Publication type:
    Article
    27

    Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.

    Published in:
    Modern Rheumatology, 2024, v. 34, n. 2, p. 272, doi. 10.1093/mr/road063
    By:
    • Masataka Kuwana;
    • Naonobu Sugiyama;
    • Shigeki Momohara;
    • Tatsuya Atsumi;
    • Syuji Takei;
    • Naoto Tamura;
    • Masayoshi Harigai;
    • Takao Fujii;
    • Hiroaki Matsuno;
    • Tsutomu Takeuchi;
    • Kazuhiko Yamamoto;
    • Yoshinari Takasaki;
    • Miki Tanigawa;
    • Yutaka Endo;
    • Tomohiro Hirose;
    • Yosuke Morishima;
    • Noritoshi Yoshii;
    • Tsuneyo Mimori;
    • Michiaki Takagi
    Publication type:
    Article